# US 2024/0199656 A1 · Boron neutron capture therapy (bnct) probe

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199656 A1
- Document ID: US20240199656A1
- Status: Published application
- Kind: A1
- Application number: 18/277,623
- Filed: 2022-02-21
- Published: 2024-06-20
- Earliest claimed: 2021-02-19
- Assignees: The University of Tokyo
- Applicants: The University of Tokyo
- Inventors: Yasuteru URANO; Mako KAMIYA; Junya TSUNETOMI
- Web page: https://patentgrep.com/patent/US20240199656A1

## CPC

- C07F 5/027: {Organoboranes and organoborohydrides}
- A61K 41/0095: {Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins}
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 51/04: Organic compounds
- A61P 35/00: Antineoplastic agents
- C07F 5/02: Boron compounds
- C07F 5/025: {Boronic and borinic acid compounds}
- C07F 5/05: Cyclic compounds having at least one ring containing boron but no carbon in the ring
- A61N 5/1077: {Beam delivery systems}
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

[Problem] To provide a novel compound promising as a probe for a boron neutron capture therapy (BNCT). [Solution] A compound represented by general formula (I) below or a salt thereof.

## Claims

### Claim 1

A compound represented by the following General Formula (I) or a salt thereof.
in the formula,
X is selected from the group consisting of a fluorine atom, an ester group (—OC(═O)—R′), a carbonate group (—OCO2—R′), a carbamate group (—OCONH—R′), phosphoric acid and an ester group thereof (—OP(═O)(—OR′)(—OR″)), and sulfuric acid and an ester group thereof (—OSO2—OR′),
where R′ and R″ are each independently selected from a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group;
Y is —NH—CO-L, —NH-L′, or —OL′,
where L is a partial structure of an amino acid,
L′is a saccharide or a partial structure of a saccharide, a saccharide having a self-cleaving linker, or an amino acid or a peptide having a self-cleaving linker;
R1 and R2 are each independently selected from a hydrogen atom or a monovalent substituent;
R3 is a hydrogen atom or one to three identical or different monovalent substituents present on a benzene ring;
Z represents a single bond or a linking group; and
B represents a group containing 10B.

### Claim 2 (depends on 1)

The compound or a salt thereof according to claim 1, wherein B is a group derived from a compound having at least one boron atom in a molecule.

### Claim 3 (depends on 1)

The compound or a salt thereof according to claim 1, wherein B is a group derived from a boron cluster.

### Claim 4 (depends on 3)

The compound or a salt thereof according to claim 3, wherein the boron cluster has a polyhedral structure.

### Claim 5 (depends on 1)

The compound or a salt thereof according to claim 1, wherein B is a group derived from closo-dodecaborate, closo-carborane, nidocarborane, a bisdicarbolide metal complex, GB10, 1,2-dicarbacloso-dodecarborane, 1,7-dicarba-closo-dodecarborane, 1,12-dicarba-closo-dodecarborane, dicarba-closo-decarborane, or sulfur-substituted undecahydrododecaborate.

### Claim 6 (depends on 1)

The compound or a salt thereof according to claim 1, wherein the linking group is selected from the group consisting of an alkylene group (where one or more —CH2— of the alkylene group may be replaced by —O—, —S—, —NH—, or —CO—), arylene (including heteroarylene), cycloalkylene, an alkoxyl group, a polyethylene glycol chain, and a group constituted by optionally binding two or more groups selected from these groups.

### Claim 7 (depends on 1)

The compound or a salt thereof according to claim 1, wherein the partial structure of the amino acid of L constitutes an amino acid, an amino acid residue, a peptide, or a part of an amino acid together with C═O to which L is bonded.

### Claim 8 (depends on 1)

The compound or a salt thereof according to claim 1, wherein the partial structure of the saccharide of L′ constitutes a saccharide or a part of a saccharide together with O to which L′is bonded.

### Claim 9 (depends on 1)

The compound or a salt thereof according to claim 1, wherein —Y in General Formula (I) is bonded to —C(R1)(R2)X at an ortho position or a para position of a benzene ring.

### Claim 10 (depends on 1)

The compound or a salt thereof according to claim 1, wherein Y has a structure selected from the following:

### Claim 11 (depends on 1)

The compound or a salt thereof according to claim 1, wherein X is a fluorine atom or an ester group (—OC(═O)—R′).

### Claim 12 (depends on 1)

The compound or a salt thereof according to claim 1, wherein R1 and R2 are each independently selected from a hydrogen atom or a fluorine atom.

### Claim 13 (depends on 1)

The compound or a salt thereof according to claim 1, wherein the monovalent substituent of R3 is selected from the group consisting of an alkyl group, an alkoxycarbonyl group (—C(═O)—OR′), a nitro group, an amino group, a hydroxyl group, an alkylamino group (—NHR′ or —NR′2—NHCOR′), an alkoxy group (—OR′), an ester group (—O—CO—R′), an amide group (—NHCOR′), a halogen atom, a boryl group, and a cyano group, where R′ is a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group, and when there are two or more R's, R's may be the same as or different from each other.

### Claim 14 (depends on 13)

The compound or a salt thereof according to claim 13, wherein the monovalent substituent of R3 is an alkyl group or an alkoxy group.

### Claim 15 (depends on 13)

The compound or a salt thereof according to claim 13, wherein the monovalent substituent of R3 is a halogen atom.

### Claim 16 (depends on 13)

The compound or a salt thereof according to claim 13, wherein one or more of the monovalent substituents of R3 are alkyl groups or alkoxy groups, and one or more of the monovalent substituents of R3 are halogen atoms.

### Claim 17 (depends on 1)

The compound or a salt thereof according to claim 1, wherein all of R3s are hydrogen atoms.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The pharmaceutical composition according to claim 18, wherein the pharmaceutical composition is used in a boron neutron capture therapy.

### Claim 20 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the pharmaceutical composition is accumulated in cancer cells by acting selectively on cells by a cancer cell-specific enzyme activity.

### Claim 21 (depends on 20)

The pharmaceutical composition according to claim 20, wherein the enzyme is a peptidase or a glycosidase.

### Claim 22 (depends on 1)

A method for diagnosing, treating, or diagnosing and treating a disease or a symptom that may cause the disease, the method comprising:
(A) administering, to a subject having or suspected of having a disease or a symptom, a pharmaceutical composition comprising the compound according claim 1 or a pharmaceutically acceptable salt thereof; and
(B) irradiating a 10B atom localized in a target tissue of the subject with a neutron beam to perform a boron neutron capture therapy on the target tissue.
